Related Experiment Video
Updated: Jun 26, 2025
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
Published on: January 7, 2015
Role of Colchicine in Cardiovascular Disorders
Errol Moras1, Lakshmi Subramanian2, Francisco Romeo3
1From the Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Insights
Low-dose colchicine shows promise as a targeted anti-inflammatory therapy for cardiovascular disease, reducing major adverse cardiovascular events. Careful monitoring of side effects and drug interactions is crucial for safe and effective use in patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Inflammation Research
Background:
- Inflammation is a key driver of atherosclerosis and cardiovascular diseases.
- Colchicine, traditionally used for gout, is now recognized for its anti-inflammatory cardiovascular benefits.
- Residual inflammatory risk remains a challenge in cardiovascular disease management.
Purpose of the Study:
- To review the mechanisms of action, targets, and pharmacokinetics of colchicine in cardiovascular conditions.
- To summarize the evidence on the safety and efficacy of colchicine for cardiovascular disorders.
- To highlight colchicine as a novel, targeted anti-inflammatory therapy for cardiovascular disease.
Main Methods:
- Comprehensive literature review of landmark trials and clinical studies.
- Analysis of colchicine's molecular and biochemical targets in cardiovascular disease.
- Evaluation of pharmacokinetic data and safety profiles, including adverse effects and drug interactions.
Main Results:
- Landmark trials demonstrate that low-dose colchicine reduces major adverse cardiovascular events when added to standard therapies.
- Colchicine effectively targets both traditional risk factors and residual inflammatory risk.
- Major cardiovascular societies endorse colchicine as a first-line targeted anti-inflammatory therapy.
Conclusions:
- Colchicine represents a new era in cardiovascular prevention and treatment.
- Its efficacy and safety in conditions like coronary artery disease, pericarditis, atrial fibrillation, and heart failure are supported by robust evidence.
- Close monitoring for potential adverse effects and drug interactions is essential for optimizing colchicine therapy.
Abstract:
Inflammation has played a pivotal role in atherosclerosis and other cardiovascular disorders, prompting the exploration of anti-inflammatory therapies to improve cardiovascular outcomes. Colchicine, a well-established agent in conditions such as gout and familial Mediterranean fever, has emerged as a promising novel anti-inflammatory agent in the realm of cardiovascular diseases. Its ability to target both traditional risk factors and residual inflammatory risk marks a significant advancement in cardiovascular prevention strategies, indicating a new era in cardiovascular care. Landmark trials have supported the efficacy and safety of low-dose colchicine in reducing major adverse cardiovascular events when combined with standard therapies. In addition, its endorsement by major cardiovascular societies underscores its significance as the first targeted anti-inflammatory therapy for cardiovascular disease. However, careful monitoring for drug interactions and adverse effects, particularly on kidney and liver function, is essential for safe use. In this review, we aim to comprehensively summarize the mechanisms of action of colchicine, its molecular and biochemical targets in various cardiovascular conditions, and its pharmacokinetics, and delve deeply into the existing evidence on its safety and efficacy in the treatment of cardiovascular disorders, including coronary artery disease, pericarditis, atrial fibrillation, and heart failure.
More Related Videos
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:20Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
01:26Heart Failure Drugs: Inotropic Agents